- |||||||||| Review, Journal: A myasthenic crisis of broken hearts (reverse takotsubo): Case report and review of literature. (Pubmed Central) - Sep 30, 2022
TTC is an important differential diagnosis in acute deteriorations of cardiac function, particularly in intensive care, not only due to frequent use of inotropes and embolic complications but also because cardiac function is reversible with good medical care. Early specialist neurologist and cardiologist input should be sought in such cases.
- |||||||||| Journal: Bilateral medial medullary stroke: A rare stroke syndrome masquerading as myasthenia crisis in a young diabetic lady. (Pubmed Central) - Sep 30, 2022
Her case was subsequently diagnosed as bilateral medial medullary stroke, following evolving clinical signs and magnetic resonance imaging (MRI) findings of a heart-shaped abnormality at the rostral medulla. This rare stroke syndrome represented a diagnostic challenge which necessitated a strong clinical suspicion and an urgent MRI scan of the brain for prompt diagnosis to enable appropriate treatment initiation.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Journal: Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. (Pubmed Central) - Sep 30, 2022 Eculizumab, a C5-inhibitor, is the only approved treatment for MG that mechanistically addresses complement-mediated loss of nicotinic acetylcholine receptors...To enable identification of MG patients that are likely to respond to C7 inhibition, we developed a patient stratification assay and showed in a small cohort of MG patients (n=19) that 63% had significant complement activation and C7-dependent loss of AChRs in this in vitro set up. This study provides validation of C7 as a target for treatment of MG and provides a means of identifying patients likely to respond to anti-C7 therapy based on complement-activating properties of patient autoantibodies.
- |||||||||| Review, Journal: Anterior chest wall lifting methods for mediastinal approach-literature review. (Pubmed Central) - Sep 29, 2022
Thoracoscopic surgery for the treatment of anterior mediastinal lesions was introduced in the 1990s. Particularly in cases of surgery in the supine position, various creative methods and devices of lifting the sternum body, the anterior part of the rib, or the xiphoid process were reported.
- |||||||||| Journal: Familial autoimmunity in patients with idiopathic inflammatory myopathies. (Pubmed Central) - Sep 29, 2022
It is important to conduct a comprehensive evaluation to assess all aspects of the velopharyngeal function. The observed familial associations may suggest that IIM shares genetic susceptibility with various ADs, information that may be useful for clinical counselling and guiding future genetic studies of IIM.
- |||||||||| Journal: Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. (Pubmed Central) - Sep 29, 2022
We also found that the onset age shifted to the elderly, and the male-female ratio reached almost even. Classification in four categories; AChRAb(+)Tm(-), AChRAb(+)Tm(+), MuSKAb(+), and DN, well describe the specific clinical features of each category and differences in therapeutic approaches.
- |||||||||| Review, Journal: Pediatric Thymoma: A Review and Update of the Literature. (Pubmed Central) - Sep 24, 2022
An association between stage and outcome, and completeness of resection and outcome, was found. Interestingly, though an association between histotype and staging was found, this does not take into account the possibility of mixed histologies which would reduce the clinical impact of histologic subtyping over staging.
- |||||||||| Journal: Neurological outcomes of extended thymectomy for thymomatous myasthenia gravis: Subxiphoid vs. trans-sternal approaches. (Pubmed Central) - Sep 24, 2022
The multivariate model including age ≦48 (HR = 1.837, 95% CI, 1.093-3.086, P = 0.022) and the subxiphoid approach (HR = 1.892, 95% CI, 1.127-3.177, P = 0.016) was significantly associated with a faster improvement in clinical status. In patients with Masaoka stage I and II thymoma who underwent thymectomy, with tumor size less than 5 cm and thymomatous MG, age ≦48 years and the subxiphoid approach were associated with a rapid improvement in clinical status.
- |||||||||| Journal: Paraneoplastic pemphigus associated with Castleman disease: A multicenter case series. (Pubmed Central) - Sep 23, 2022
Patients with MCD, incomplete resection, and BO died; patients with UCD and complete resection remain alive, even in the setting of BO. Consideration of PNP is critical when pediatric patients present with mucositis as PNP may be clinically indistinguishable from more common causes of mucositis.
- |||||||||| Journal: Disease-Drug Interactions Requiring Special Attention. (Pubmed Central) - Sep 21, 2022
These include awareness, regular diagnosis- and drug-history taking, consulting the product information, good communication between healthcare providers and patient education. Furthermore, pharmacovigilance activities help in the early identification and characterization of adverse drug reactions resulting from disease-drug interactions.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Neurology of cancer immunotherapy. (Pubmed Central) - Sep 20, 2022 There are predominances of men in P-LEMS and women in AI-LEMS. In this article, we describe the most frequently reported NAEs and aim to give neurologists a practical overview on how to deal with them.
- |||||||||| Journal: New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series. (Pubmed Central) - Sep 20, 2022
MG is a rare disease; clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses. The hyperstimulation of the innate immune system or the exacerbation of a subclinical pre-existing MG could be possible explanations.
- |||||||||| nipocalimab (M281) / J&J
Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_3521; P1, P2 These data suggest that nipocalimab can selectively lower IgG and IgG autoantibodies while preserving cellular immunity, complete IgM response and IgG production after neoantigen challenge. Overall, nipocalimab's selective effect on IgG recycling provides a mechanistic rationale for potentially decreased infection risk despite substantial IgG lowering
|